Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Steveo10on Mar 25, 2019 11:43pm

103 Views

Post# 29534903

RE:RE:RE:Going back up in short order

PENNYPATROL wrote: Enjoy what ride? The 52 week high was around $.32 look at where it is now. I’m long and strong but there hasn’t been much going on and disappointed with management to say the least. People in the know are aware of the news before it comes out and they buy millions of shares and then dump it on the news.

Indeed. Just fell through some more support today. Could see the 7s tomorrow :(

Bullboard Posts

Eminent acquires promising Nevada gold project